Impact of ACEI/ARB use on the survival of hypertensive patients with cancer: A meta‑analysis
- Authors:
- Yao Xiao
- Xinlong Chen
- Wancheng Li
- Xin Li
- Wence Zhou
-
Affiliations: Department of General Surgery, The Second Clinical Medical College, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China, Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi 710061, P.R. China - Published online on: September 5, 2024 https://doi.org/10.3892/ol.2024.14667
- Article Number: 534
-
Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
|
Wang MC and Lloyd-Jones DM: Cardiovascular risk assessment in hypertensive patients. Am J Hypertens. 34:569–577. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Małyszko J, Małyszko M, Kozlowski L, Kozlowska K and Małyszko J: Hypertension in malignancy-an underappreciated problem. Oncotarget. 9:20855–20871. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A and Gandini S: Use of beta-blockers and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. Int J Cancer. 139:212–219. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Deng Y, Xie Y, Wang M, Xu P, Wei B, Li N, Wu Y, Yang S, Zhou L, Hao Q, et al: Effects of antihypertensive drugs use on risk and prognosis of colorectal cancer: A meta-analysis of 37 observational studies. Front Pharmacol. 12:6706572022. View Article : Google Scholar : PubMed/NCBI | |
|
Allen AM: Role of angiotensin in the rostral ventrolateral medulla in the development and maintenance of hypertension. Curr Opin Pharmacol. 11:117–123. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Dinh DT, Frauman AG, Johnston CI and Fabiani ME: Angiotensin receptors: Distribution, signalling and function. Clin Sci (Lond). 100:481–492. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC Jr, Llorens-Cortes C, Ehlers MR and Sturrock ED: Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 71:539–570. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Escobar E, Rodríguez-Reyna TS, Arrieta O and Sotelo J: Angiotensin II and cell proliferation and angiogenesis regulator: Biologic and therapeutic implications in cancer. Curr Vasc Pharmacol. 2:385–399. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ram CV: Antihypertensive drugs: An overview. Am J Cardiovasc Drugs. 2:77–89. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Neo JH, Malcontenti-Wilson C, Muralidharan V and Christophi C: Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol. 22:577–584. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S and Pocock S; CHARM Investigators Committees, : Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet. 362:759–766. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tamburrino D, Guarneri G, Partelli S, Crippa S, Falconi M and Capurso G: Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma? Dig Liver Dis. 53:1065–1067. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Higgins JPT and Green S: Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration. 2011.Available from. www.handbook.cochrane.org | |
|
Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group, : Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009. View Article : Google Scholar : PubMed/NCBI | |
|
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from URL:. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm[cited 2009 Oct 19]. | |
|
Anderson JL, Knowlton KU, Muhlestein JB, Bair TL, Le VT and Horne BD: Evaluation of treatment with angiotensin converting enzyme inhibitors and the risk of lung cancer: ERACER-an observational cohort study. J Cardiovasc Pharmacol Ther. 26:321–327. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Aydiner A, Ciftci R and Sen F: Renin-angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib. Medicine (Baltimore). 94:e8872015. View Article : Google Scholar : PubMed/NCBI | |
|
Balkrishnan R, Desai RP, Narayan A, Camacho FT, Flausino LE and Chammas R: Associations between initiating antihypertensive regimens on stage I–III colorectal cancer outcomes: A medicare SEER cohort analysis. Cancer Med. 10:5347–5357. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, Zanelotti A, Adamoli L, Colleoni M, Viale G, et al: Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 140:567–575. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Busby J, McMenamin Ú, Spence A, Johnston BT, Hughes C and Cardwell CR: Angiotensin receptor blocker use and gastro-oesophageal cancer survival: A population-based cohort study. Aliment Pharmacol Ther. 47:279–288. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cardwell CR, Mc Menamin ÚC, Hicks BM, Hughes C, Cantwell MM and Murray LJ: Drugs affecting the renin-angiotensin system and survival from cancer: A population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med. 12:282014. View Article : Google Scholar : PubMed/NCBI | |
|
Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM and Chavez-Macgregor M: Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer. 4:549–556. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cho MA, Jeong SY, Sohn I, Kim MS, Kang JH, Paik ES, Lee YY and Choi CH: Impact of angiotensin receptor blockers, beta blockers, calcium channel blockers and thiazide diuretics on survival of ovarian cancer patients. Cancer Res Treat. 52:645–654. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cui Y, Wen W, Zheng T, Li H, Gao YT, Cai H, You M, Gao J, Yang G, Zheng W, et al: Use of antihypertensive medications and survival rates for breast, colorectal, lung, or stomach cancer. Am J Epidemiol. 188:1512–1528. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Engineer DR, Burney BO, Hayes TG and Garcia JM: Exposure to ACEI/ARB and β-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl Oncol. 6:539–545. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eskelinen T, Veitonmäki T, Kotsar A, Tammela TLJ, Pöyhönen A and Murtola TJ: Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes Control. 33:313–320. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fiala O, Ostasov P, Sorejs O, Liska V, Buchler T, Poprach A and Finek J: Incidental use of beta-blockers is associated with outcome of metastatic colorectal cancer patients treated with bevacizumab-based therapy: A single-institution retrospective analysis of 514 patients. Cancers (Basel). 11:18562019. View Article : Google Scholar : PubMed/NCBI | |
|
Fiala O, Ostašov P, Rozsypalová A, Hora M, Šorejs O, Šustr J, Bendová B, Trávníček I, Filipovský J, Fínek J and Büchler T: Impact of concomitant cardiovascular medication on survival of metastatic renal cell carcinoma patients treated with sunitinib or pazopanib in the first line. Target Oncol. 16:643–652. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sørensen HT and Friis S: A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer. 92:1302–1306. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ganz PA, Habel LA, Weltzien EK, Caan BJ and Cole SW: Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: Results from the LACE cohort. Breast Cancer Res Treat. 129:549–556. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Harding BN, Delaney JA, Urban RR and Weiss NS: Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer. Gynecol Oncol. 154:426–431. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Holmes S, Griffith EJ, Musto G and Minuk GY: Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study. Cancer Epidemiol. 37:881–885. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang T, Townsend MK, Dood RL, Sood AK and Tworoger SS: Antihypertensive medication use and ovarian cancer survival. Gynecol Oncol. 163:342–347. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Keith SW, Maio V, Arafat HA, Alcusky M, Karagiannis T, Rabinowitz C, Lavu H and Louis DZ: Angiotensin blockade therapy and survival in pancreatic cancer: A population study. BMC Cancer. 22:1502022. View Article : Google Scholar : PubMed/NCBI | |
|
Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H and Carducci MA: Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur J Cancer. 47:1955–1961. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Shin SW and Kim YH: How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology. 83:354–360. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Iede K, Yamada T, Ueda M, Tsuda Y, Nakashima S, Ohta K, Tanida T, Matsuyama J, Ikenaga M and Tominaga S: Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer. Medicine (Baltimore). 101:e295322022. View Article : Google Scholar : PubMed/NCBI | |
|
Li PC, Huang RY, Yang YC, Hsieh KP and Yang YH: Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension-a real-world study. BMC Cancer. 22:4302022. View Article : Google Scholar : PubMed/NCBI | |
|
Lin YT, Wang HC, Tsai MH, Su YY, Yang MY and Chien CY: Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma. Cancer. 127:1606–1619. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lorona NC, Cook LS, Tang MTC, Hill DA, Wiggins CL and Li CI: Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. Cancer Causes Control. 32:1375–1384. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mafiana RN, Al-Kindi MS, Mafiana N, Al Lawati AS and Al Moundhri M: Impact of metabolic syndrome diagnosis and its treatment on survival of colorectal cancer patients. J Cancer Epidemiol. 2019:65274572019.PubMed/NCBI | |
|
Ho CM, Lee CH, Lee MC, Zhang JF, Wang JY, Hu RH and Lee PH: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: A nationwide high-risk cohort study. BMC Cancer. 18:4012018. View Article : Google Scholar : PubMed/NCBI | |
|
Morris ZS, Saha S, Magnuson WJ, Morris BA, Borkenhagen JF, Ching A, Hirose G, McMurry V, Francis DM, Harari PM, et al: Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer. 122:2487–2495. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, et al: Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 103:1644–1648. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, et al: The inhibition of renin-angiotensin system in advanced pancreatic cancer: An exploratory analysis in 349 patients. J Cancer Res Clin Oncol. 141:933–939. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS and Hamilton RJ: Canadian Drug Safety and Effectiveness Research Network (CDSERN): Medication use and kidney cancer survival: A population-based study. Int J Cancer. 142:1776–1785. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E and Mizunuma N: Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol Clin Oncol. 3:1295–1300. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ozawa T, Hashiguchi Y, Yagi T, Fukushima Y, Shimada R, Hayama T, Tsuchiya T, Nozawa K, Iinuma H, Ishihara S and Matsuda K: Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers. Int J Colorectal Dis. 34:1731–1739. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Santala EEE, Kotsar A, Veitonmäki T, Tammela TLJ and Murtola TJ: Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland. Scand J Urol. 53:185–192. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Santala EEE, Murto MO, Artama M, Pukkala E, Visvanathan K and Murtola TJ: Angiotensin receptor blockers associated with improved breast cancer survival-a nationwide cohort study from Finland. Cancer Epidemiol Biomarkers Prev. 29:2376–2382. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Santala EE, Rannikko A and Murtola TJ: Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study. Int J Cancer. 144:440–447. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ and Auvinen A: Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS One. 15:e02342692020. View Article : Google Scholar : PubMed/NCBI | |
|
Santala EEE, Artama M, Pukkala E, Visvanathan K, Staff S and Murtola TJ: Antihypertensive drug use and the risk of ovarian cancer death among Finnish ovarian cancer patients-a nationwide cohort study. Cancers (Basel). 13:20872021. View Article : Google Scholar : PubMed/NCBI | |
|
Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ and Auvinen A: Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scand J Urol. 52:321–327. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Støer NC, Bouche G, Pantziarka P, Sloan EK, Andreassen BK and Botteri E: Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: A nationwide registry-based study in Norway. Acta Oncol. 60:1146–1153. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Stokes WA, Molina E, McDermott JD, Morgan RL, Bickett T, Fakhoury KR, Amini A and Karam SD: Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer. Head Neck. 43:3255–3275. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wilk M, Waśko-Grabowska A, Skoneczna I and Szmit S: Angiotensin system inhibitors may improve outcomes of patients with castration-resistant prostate cancer during abiraterone acetate treatment-a cardio-oncology study. Front Oncol. 11:6647412021. View Article : Google Scholar : PubMed/NCBI | |
|
Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R and Jost E: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 135:1429–1435. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wu CN, Wu SC, Chen WC, Yang YH, Chin JC, Chien CY, Fang FM, Li SH, Luo SD and Chiu TJ: Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study. PLoS One. 16:e02607722021. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida T, Kinoshita H, Fukui K, Matsuzaki T, Yoshida K, Mishima T, Yanishi M, Komai Y, Sugi M, Inoue T, et al: Prognostic impact of renin-angiotensin inhibitors in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol. 24:823–831. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Song M, Chan AT, Meyerhardt JA, Willett WC and Giovannucci EL: Long-term use of antihypertensive medications and hypertension and colorectal cancer risk mortality: A prospective cohort study. Br J Cancer. 127:1974–1982. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Yang A, Wu H, Lau ESH, Shi M, Fan B, Kong APS, Ma RCW, Luk AOY, Chan JCN and Chow E: Effects of RAS inhibitors on all-site cancers and mortality in the Hong Kong diabetes surveillance database (2002–2019). EBioMedicine. 83:1042192022. View Article : Google Scholar : PubMed/NCBI | |
|
Israili ZH, Hernández-Hernández R and Valasco M: The future of antihypertensive treatment. Am J Ther. 14:121–134. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Li XY, Sun JF and Hu SQ: The renin-angiotensin system blockers as adjunctive therapy for cancer: A meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci. 21:1375–1383. 2017.PubMed/NCBI | |
|
Deshayes F and Nahmias C: Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab. 16:293–299. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mc Menamin ÚC, Murray LJ, Cantwell MM and Hughes CM: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: A systematic review. Cancer Causes Control. 23:221–230. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Lam ASM, Yau STY, Yiu KKL and Tsoi KKF: Antihypertensive treatments and risks of lung cancer: A large population-based cohort study in Hong Kong. BMC Cancer. 21:12022021. View Article : Google Scholar : PubMed/NCBI | |
|
Mehrdad SA, Mirzavi F, Seyedi SMR and Asoodeh A: The effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on progression of gastric cancer: Systematic review and meta-analysis. Anticancer Drugs. 33:983–988. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH and Danser AH: Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 116:960–975. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA and Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:205–251. 1993.PubMed/NCBI | |
|
Burnier M: Angiotensin II type 1 receptor blockers. Circulation. 103:904–912. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hassani B, Attar Z and Firouzabadi N: The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: Foes versus allies. Cancer Cell Int. 23:2542023. View Article : Google Scholar : PubMed/NCBI | |
|
Imai N, Hashimoto T, Kihara M, Yoshida S, Kawana I, Yazawa T, Kitamura H and Umemura S: Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest. 87:189–198. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Judd SJ, Alderman J, Bowden J and Michailov L: Evidence against the involvement of opiate neurons in mediating the effect of clomiphene citrate on gonadotropin-releasing hormone neurons. Fertil Steril. 47:574–578. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Pei N, Mao Y, Wan P, Chen X, Li A, Chen H, Li J, Wan R, Zhang Y, Du H, et al: Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer. J Exp Clin Cancer Res. 36:772017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Fan J, Wu F, Huang Q, Guo M, Lv Z, Han J, Duan L, Hu G, Chen L, et al: The ACE2/angiotensin-(1–7)/Mas receptor axis: Pleiotropic roles in cancer. Front Physiol. 8:2762017. View Article : Google Scholar : PubMed/NCBI | |
|
Ferreira AJ and Santos RA: Cardiovascular actions of angiotensin-(1–7). Braz J Med Biol Res. 38:499–507. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, et al: AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA. 106:10284–10289. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Weigelt B, Geyer FC and Reis-Filho JS: Histological types of breast cancer: How special are they? Mol Oncol. 4:192–208. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cushman DW and Ondetti MA: History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension. 17:589–592. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Burch RM, Farmer SG and Steranka LR: Bradykinin receptor antagonists. Med Res Rev. 10:237–269. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Montana V and Sontheimer H: Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci. 31:4858–4867. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng CY, Kuo CT, Lin CC, Hsieh HL and Yang CM: IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells. Br J Pharmacol. 160:1595–1610. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HS, Lin TH and Tang CH: Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers. Int J Mol Sci. 14:13329–13345. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hill RD and Vaidya PN: Angiotensin II receptor blockers (ARB). StatPearls [Internet]. StatPearls Publishing; Treasure Island, FL: 2024 | |
|
Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 57 (Suppl 1):S3–S7. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Colin M, Delaitre C, Foulquier S and Dupuis F: The AT1/AT2 receptor equilibrium is a cornerstone of the regulation of the renin angiotensin system beyond the cardiovascular system. Molecules. 28:54812023. View Article : Google Scholar : PubMed/NCBI | |
|
Kidoguchi S, Sugano N, Yokoo T, Kaneko H, Akazawa H, Mukai M, Node K, Yano Y and Nishiyama A: Antihypertensive drugs and cancer risk. Am J Hypertens. 35:767–783. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tsioufis C and Thomopoulos C: Combination drug treatment in hypertension. Pharmacol Res. 125:266–271. 2017. View Article : Google Scholar : PubMed/NCBI |
